Skip to main content
. 2023 May 9;30(3):423–428. doi: 10.1093/ibd/izad073

Table 2.

Maintenance subcutaneous ustekinumab doses prescribed to study subjects.

Ustekinumab dose 90mg Ustekinumab dose 180mg
12 weekly 1.9% (n = 1) 8 weekly 1.9% (n = 1)
8 weekly 64.2% (n = 34) 4 weekly 17% (n = 9)
6 weekly 7.5% (n = 4)
4 weekly 7.5% (n = 4)